Cargando…

A152 NATURAL HISTORY OF SMALL BOWEL STRICTURES IN CROHN’S DISEASE

BACKGROUND: Crohn’s disease (CD) is a progressive inflammatory disease that often results in intestinal complications such as small bowel (SB) strictures. SB strictures are frequently associated with substantial morbidity and may require surgery. The natural history of SB strictures in the era of bi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vu, D C, Brar, G S, Dadgar, K, McCurdy, J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Poster of Distinction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859125/ http://dx.doi.org/10.1093/jcag/gwab049.151

Ejemplares similares

A153 STRATEGIES TO DISTINGUISH PERIANAL FISTULAS RELATED TO CROHN’S DISEASE FROM CRYPTOGLANDULAR DISEASE: SYSTEMATIC REVIEW WITH META-ANALYSIS
por: Chin Koon Siw, K, et al.
Publicado: (2022)

A151 RISK FACTORS FOR VENOUS THROMBOEMBOLISM AFTER HOSPITAL DISCHARGE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Gozdzik, M, et al.
Publicado: (2022)

A201 A CASE OF SYPHILIS MASQUARADING AS CROHN’S DISEASE
por: Smith, B C, et al.
Publicado: (2022)

A156 MUCOSA-ASSOCIATED MICROBIOTA OF ILEOCOLONIC CROHN’S DISEASE PATIENTS IS DISTINCT FROM COLONIC CROHN’S DISEASE AND ULCERATIVE COLITIS PATIENTS INDEPENDENT OF BIOPSY SITE, ENDOSCOPIC INFLAMMATION AND HOST GENETICS
por: Hernandez-Rocha, C, et al.
Publicado: (2022)

A179 AUTOLOGOUS BONE MARROW TRANSPLANT FOR REFRACTORY CROHN’S DISEASE: A CASE SERIES
por: Buttar, J, et al.
Publicado: (2022)

A150 ASSOCIATION BETWEEN SERUM USTEKINUMAB CONCENTRATIONS AND ENDOSCOPIC DISEASE ACTIVITY IN CROHN’S DISEASE
por: Yanofsky, R, et al.
Publicado: (2022)

A51 ROLE OF GUT MICROBIOTA IN THE EPISODIC NATURE OF SYMPTOMS IN IRRITABLE BOWEL SYNDROME
por: Mohan, V, et al.
Publicado: (2022)

A154 COMPARING RESPONSE TO INTRAVENOUS IRON INFUSION IN CROHN’S DISEASE AND ULCERATIVE COLITIS
por: Su, S, et al.
Publicado: (2022)

A24 GENERALIZABILITY OF CROHN’S DISEASE RANDOMIZED CONTROLLED TRIALS COMPARED TO CLINICAL PRACTICE
por: Chhibba, T, et al.
Publicado: (2022)

A186 CHANGES IN THE CLINICAL PHENOTYPE AND BEHAVIOR OF PEDIATRIC LUMINAL CROHN’S DISEASE AT DIAGNOSIS IN THE LAST DECADE
por: Sassine, S, et al.
Publicado: (2022)

A176 UTILITY OF MACHINE LEARNING FOR SERUM METABOLOMIC DATA ANALYSIS IN PEDIATRIC CROHN DISEASE
por: Suarez Suarez, R G, et al.
Publicado: (2022)

A236 ASSOCIATION OF STOOL METABOLOMIC PROFILE AND MICROBIOME COMPOSITION RISK SCORE WITH FUTURE ONSET OF CROHN’S DISEASE
por: Lee, S, et al.
Publicado: (2022)

A188 FACTORS ASSOCIATED WITH CLINICAL REMISSION IN PEDIATRIC LUMINAL CROHN’S DISEASE: A RETROSPECTIVE COHORT STUDY
por: Sassine, S, et al.
Publicado: (2022)

A187 RISK FACTORS OF CLINICAL RELAPSES IN PEDIATRIC LUMINAL CROHN’S DISEASE, A RETROSPECTIVE COHORT STUDY
por: Sassine, S, et al.
Publicado: (2022)

A81 TRANSITION PRACTICES FROM PEDIATRIC TO ADULT CARE OF CHILDREN LIVING WITH CROHN’S DISEASE IN QUEBEC
por: Gong, R, et al.
Publicado: (2022)

A238 ALTERED GUT MICROBIOME COMPOSITION AND FUNCTION ARE ASSOCIATED WITH GUT BARRIER DYSFUNCTION IN HEALTHY RELATIVES OF CROHN’S DISEASE PATIENTS
por: Leibovitzh, H, et al.
Publicado: (2022)

A29 HIGH DIMENSIONAL SINGLE CELL ANALYSIS OF IL-4 TREATED MACROPHAGES REVEALS A HETEROGENIC PHENOTYPE AND THE ABSENCE OF CD206+ SUBSETS IN CROHN'S DISEASE PATIENTS
por: Callejas, B E, et al.
Publicado: (2023)

A38 INVESTIGATION OF POST-TRANSLATIONAL MODIFICATIONS IN SERUM OF CROHN’S DISEASE PATIENTS USING A PROTEOMICS APPROACH
por: De Almeida, L G N, et al.
Publicado: (2023)

A163 EVALUATING THE ASSOCIATION BETWEEN PERIPHERAL BLOOD EOSINOPHILS AND DRUG RESPONSE IN CROHN’S DISEASE: A PRELIMINARY REPORT
por: Cai, B, et al.
Publicado: (2022)

A235 ILEAL MICROBIOME ALPHA DIVERSITY REMAINS LOWER IN ENDOSCOPICALLY AND HISTOLOGICALLY INACTIVE CROHN’S DISEASE COMPARED TO ULCERATIVE COLITIS OR HEALTHY CONTROLS
por: Olivera Sendra, P A, et al.
Publicado: (2022)

A37 EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN’S DISEASE: 52 WEEK RESULTS FROM THE PHASE 3 FORTIFY STUDY
por: Panaccione, R, et al.
Publicado: (2022)

A65 PREDICTING TRANSITION SUCCESS IN YOUNG ADULTS WITH INFLAMMATORY BOWEL DISEASE: PRELIMINARY RESULTS
por: Bihari, A, et al.
Publicado: (2022)

A98 FECAL LEUKOCYTE ESTERASE: AN ALTERNATIVE BIOMARKER TO FECAL CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE
por: Klemm, N K, et al.
Publicado: (2022)

A161 MUCOSAL TRANSCRIPTOMICS IN NON-INFLAMED ILEUM OF CROHN’S DISEASE PATIENTS SHOWS DIFFERENTIALLY EXPRESSED GENE PROFILE COMPARED TO ILEUM OF HEALTHY CONTROLS
por: Martinez-Lozano, H, et al.
Publicado: (2022)

A175 DISEASE ACTIVITY IN FIRST TRIMESTER IS ASSOCIATED WITH REDUCED GROWTH IN INFANTS BORN TO WOMEN WITH INFLAMMATORY BOWEL DISEASE
por: Wu, R Y, et al.
Publicado: (2022)

A183 TELEHEALTH USE IN RURAL SASKATCHEWAN AND INFLAMMATORY BOWEL DISEASE OUTCOMES
por: Patterson, M, et al.
Publicado: (2021)

A170 SERUM ALBUMIN AS A MEASURE OF INFLAMMATION OR MALNUTRITION IN INFLAMMATORY BOWEL DISEASE: A CROSS SECTIONAL STUDY
por: Squirell, E, et al.
Publicado: (2022)

A185 DUAL BIOLOGIC THERAPY IN A PATIENT WITH NIEMANN-PICK TYPE C AND CROHN DISEASE: A CASE REPORT AND LITERATURE REVIEW
por: Hudson, A, et al.
Publicado: (2022)

A180 CLINICAL OUTCOMES OF COVID-19 AND IMPACT ON DISEASE COURSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Wetwittayakhlang, P, et al.
Publicado: (2022)

A233 CHARACTERIZATION OF THE DUODENAL MICROBIOME IN PEDIATRIC CELIAC AND INFLAMMATORY BOWEL DISEASE PATIENTS
por: Manoogian, J, et al.
Publicado: (2022)

A73 CANADIAN INFLAMMATORY BOWEL DISEASE MOBILE APPS: CURRENT LANDSCAPE AND NEEDS
por: Chiew, B A, et al.
Publicado: (2022)

A164 RISKS OF SKIN CANCERS PRE- AND POST-INFLAMMATORY BOWEL DISEASE DIAGNOSIS
por: Narous, M, et al.
Publicado: (2022)

A155 ASEPTIC ABSCESS SYNDROME IN INFLAMMATORY BOWEL DISEASE: A CASE REPORT
por: Tam, L, et al.
Publicado: (2022)

A171 EXPLORING PATIENT PERSPECTIVES ON A 12-WEEK, ONLINE STRESS REDUCTION INTERVENTION IN INFLAMMATORY BOWEL DISEASE
por: Hyde, A, et al.
Publicado: (2022)

A42 HETEROGENEITY IN EFFICACY AND SAFETY ENDPOINTS FOR PEDIATRIC CLINICAL TRIALS IN INFLAMMATORY BOWEL DISEASE: A NEED FOR HARMONIZATION
por: Crowley, E, et al.
Publicado: (2022)

A35 FORECASTING THE INCIDENCE AND PREVALENCE OF INFLAMMATORY BOWEL DISEASE: A CANADIAN NATION-WIDE ANALYSIS
por: Coward, S, et al.
Publicado: (2023)

A37 FECAL CALPROTECTIN IN A PEDIATRIC, POPULATION-BASED STUDY: UTILITY IN DIAGNOSIS AND INFLAMMATORY BOWEL DISEASE MONITORING
por: Smyth, M, et al.
Publicado: (2023)

A39 HEALTHY FIRST-DEGREE RELATIVES FROM MULTIPLEX FAMILIES VERSUS SIMPLEX HARBOR A HIGHER RISK OF DEVELOPING CROHN'S DISEASE AND ARE ASSOCIATED WITH SUBCLINICAL INFLAMMATION AND ALTERED MICROBIOME COMPOSITION
por: Olivera, P, et al.
Publicado: (2023)

A32 PHAGE TREATMENT DELAYS ONSET OF CROHN’S-ASSOCIATED E. COLI DRIVEN COLITIS IN MICE COLONIZED WITH A DEFINED MICROBIOTA
por: Jackson, K, et al.
Publicado: (2023)

A174 PERCEPTIONS OF CANNABIS USE IN WOMEN WITH INFLAMMATORY BOWEL DISEASE OF REPRODUCTIVE AGE: A CROSS-SECTIONAL STUDY
por: Tandon, P, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hucafe4es15upegiah2ar4djt3